Farmacy

May 17 2018

PDC*line Pharma cancer antigen – specific active immmunotherapies, pharma biotech.#Pharma #biotech

PDC LINE PHARMA

Pharma biotech

Pharma biotech

For a safe, long-lasting and easy to combine treatment of cancers

Potent effective

Induction of a strong cytotoxic immune response directed against a selection of tumour antigens

  • Scalable convenient

    Simple production of a large quantity of a highly qualified off-the-shelf product

  • Versatile applicable to any cancers

    The peptides can easily be changed to target a specific cancer type

  • Candidate products

    Pharma biotech

    Pharma biotech

    Melanoma is the most lethal form of skin cancer, representing 2% of all newly diagnosed cancer cases (232,000 new cases and 55,000 deaths worldwide in 2012). It is also the leading cancer in terms of incidence increase (+ 10% per year) and one of the most common cancers in young adults (18-35 years).

    However, it is also more likely to spread (metastasize) to other parts of the body, and 16% of patients are first diagnosed at an advanced stage. Prognosis for this late-stage disease is very unfavorable (5-year mortality rate of 85%).

    Pharma biotech

    Pharma biotech

    1.8 million new cases of lung cancer were diagnosed worldwide in 2012, and this disease was responsible for and 1.6 million deaths. Lung cancer is therefore the most frequently diagnosed cancer and the leading cause of cancer mortality.

    About 40% of patients are diagnosed with locally advanced (stage IIIb) or metastatic (stage IV) cancer; prognosis is poor (median survival 8-13 months).

    PDC*line Pharma

    Pharma biotech

    Founded in April 2014 in Grenoble (France) as a spin-off of the French Blood Bank (EFS), PDC*line Pharma is a clinical-stage biotech company that develops a new class of antigen specific active immunotherapies based on a proprietary allogeneic cell line of Plasmacytoid Dendritic cells (PDC*line).

    PDC*mel, our leading drug candidate is currently in phase 1 clinical trials for melanoma. PDC*lung is in preclinical development for lung cancer.

    Pharma biotech SUBSCRIBE TO THE PDC*LINE NEWS





    Written by admin


    Leave a Reply

    Your email address will not be published. Required fields are marked *